Inhibition of the ALT pathway by interfering with Poly-ADP-Ribose metabolism
Project Number5R01CA207209-02
Contact PI/Project LeaderO'SULLIVAN, RODERICK
Awardee OrganizationUNIVERSITY OF PITTSBURGH AT PITTSBURGH
Description
Abstract Text
Abstract
Telomeres, the natural termini of chromosomes, are composed of 10-15kb of the TTAGGG sequence and are
critical regulators of healthy cellular physiology. These structures function as guardians of genome stability by
limiting unwanted DNA repair activity at chromosome ends, and by controlling the total number of times a cell
can divide thereby limiting the accumulation of genomic instability in actively proliferating cells. The sustained
growth of cells with inherently compromised telomeric structure and function can have catastrophic
consequences as it promotes the entanglement of chromosomes that may result in chromothripsis (Greek for
“chromosome shattering”) or breakage-fusion-bridge cycles, events that are strongly linked with cancer
initiation. To prevent this from occurring, shortening or spontaneous de-protection of telomeres activates cell
cycle checkpoint signaling that triggers senescence, an essential barrier to tumor formation. In order to survive,
proliferate and eventually infiltrate tissues and organs, cancer cells must bypass replicative senescence and
activate a telomere maintenance mechanism (TMM). Most cancer cells reactivate the catalytic subunit of
telomerase, hTERT, which is widely investigated. However, hTERT is suppressed in a number of cancers.
These cancers maintain telomere length by engaging the alternative lengthening of telomeres (ALT) pathway.
Recent data indicates that ALT is activated by defective histone dynamics during chromatin assembly that
results in perturbed replication fork progression through telomeres. Though many details of ALT are poorly
understood it is anticipated that the repair of these forks occurs via break-induced replication (BIR) and
homologous recombination. These processes are thought to occur within cellular structures termed ALT
associated PML bodies, or APBs, that are unique to ALT cancer cells. The apical involvement of replication
fork repair activities in sustaining the ALT pathway is underscored by recent observations where treatment of
ALT cells with generic replication inhibitors has been shown to prevent the assembly of APBs and ALT cancer
cells display enhanced sensitivity to ATR inhibitors. In following-up several hits from a proteomic purification of
telomeres from ALT+ cells we have identified that maintaining ADP-ribose equilibrium is a critical feature of the
ALT mechanism. Depletion of a unique enzyme, poly ADP-ribose glycohyrolase (PARG), which degrades poly
ADP-ribose (PAR), disrupts APB formation and negatively impacts ALT activity. PARG is an important
regulator of DNA repair that, until now, has not been associated with telomere regulation. This study
investigates the role of PARG in cancer cells that employ ALT and analyzes the effects of its inhibition on
cancer cell survival. In AIM 1 we will investigate telomere structure in cells with suppressed PARG, as well as
the spatiotemporal dynamics of telomeres. AIM 2 is designed as an extension of our preliminary data in which
we have identified that PAR directly interferes with RPA binding to telomeres in ALT+ cells. We will employ
biochemical studies with novel PARG inhibitors and proteomics to generate insights of the mechanism
underpinning ALT inhibition by interfering with PAR degradation. Finally, in AIM 3 we will study the cellular
effects of PARG depletion and investigate the fate of cells in which ALT in inhibited.
Public Health Relevance Statement
PUBLIC HEALTH RELEVANCE:
In order to survive, proliferate and eventually infiltrate tissues and organs, it is essential that cancer
cells maintain their telomeres. This is achieved by activating one of two different telomere length
maintenance mechanisms. One is common to both normal cells and cancerous cells, whereas the
other less well understood mechanism, known as ALT, is only found in cancerous cells. Cancers that
rely on ALT tend to be among the most aggressive and patients often have a poor prognosis.
Therefore, understanding the molecular basis for the activation and maintenance of the ALT pathway
and identifying the key regulators of ALT is critically important for improving the detection and
treatment of this devastating disease. This is the focus of our study.
No Sub Projects information available for 5R01CA207209-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01CA207209-02
Patents
No Patents information available for 5R01CA207209-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01CA207209-02
Clinical Studies
No Clinical Studies information available for 5R01CA207209-02
News and More
Related News Releases
No news release information available for 5R01CA207209-02
History
No Historical information available for 5R01CA207209-02
Similar Projects
No Similar Projects information available for 5R01CA207209-02